论文部分内容阅读
心律失常合并心力衰竭应用普罗帕酮(Propafenone,PF)治疗有时需与地高辛(Digoxin,D)合用。关于两药在人体内的双重相互作用(Double interaction)国内外尚未见报道。本文利用荧光偏振免疫分析法和反相高效液相色谱法测定了12名健康志愿者两药单用和合用时体内的血药浓度变化和药动学参数,同时行心电圈监护和测定心率、血压,并记录受试者的主诉反应,首次得到了中国人两药合用时相互作用的资料。结果表明,两药合用时,血清D浓度平均升高31.57％(P<0.01)。个别受试者血压明显下降、心电图ST段下移。PF的血浓度和药物动力学参数与单用时相比无显著性变化(P>0.05)。
Arrhythmia with heart failure Propafenone (PF) is sometimes used in combination with Digoxin (D). Double interaction between two drugs in the human body (Double interaction) has not been reported at home and abroad. Fluorescence polarization immunoassay and reversed-phase high-performance liquid chromatography were used to determine the change of plasma concentration and pharmacokinetic parameters in 12 healthy volunteers when used alone and in combination. The electrocardiographic monitoring and determination of heart rate, Blood pressure, and recorded the subject’s chief complaint response, for the first time obtained the Chinese two drugs combined interaction information. The results showed that the combination of two drugs, serum D concentration increased by 31.57% (P <0.01). Individual subjects decreased blood pressure, ECG ST segment down. PF blood concentration and pharmacokinetic parameters compared with no significant change (P> 0.05).